良性甲状腺疾病和分化型甲状腺癌的放射性碘治疗剂量测定 - Suppr

Suppr

超能文献

Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma.

作者信息

Salvatori Massimo, Luster Markus

机构信息

Nuclear Medicine Institute, Policlinico Universitario A.Gemelli, Catholic University of Sacred Heart, Rome, Italy.

出版信息

Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):821-8. doi: 10.1007/s00259-010-1398-0.

DOI:10.1007/s00259-010-1398-0

PMID:20186542

Abstract

摘要

相似文献

Radioiodine therapy dosimetry in benign thyroid disease and differentiated thyroid carcinoma.良性甲状腺疾病和分化型甲状腺癌的放射性碘治疗剂量测定

Eur J Nucl Med Mol Imaging. 2010 Apr;37(4):821-8. doi: 10.1007/s00259-010-1398-0.

[Controversies in the follow-up and management of well-differentiated thyroid cancer. New answers to old questions].[分化型甲状腺癌随访与管理中的争议。对老问题的新解答]

Rev Esp Med Nucl. 2005 May-Jun;24(3):207-15. doi: 10.1157/13073795.

Evaluation of dosimetry of radioiodine therapy in benign and malignant thyroid disorders by means of iodine-124 and PET.利用碘-124和正电子发射断层显像（PET）评估放射性碘治疗良性和恶性甲状腺疾病的剂量学。

Eur J Nucl Med Mol Imaging. 2002 Jun;29(6):760-7. doi: 10.1007/s00259-002-0775-8. Epub 2002 Mar 27.

Radioiodine therapy for papillary and follicular thyroid carcinoma.放射性碘治疗乳头状和滤泡状甲状腺癌。

Eur J Nucl Med Mol Imaging. 2002 Aug;29 Suppl 2:S479-85. doi: 10.1007/s00259-002-0810-9. Epub 2002 May 9.

Quantitative radioiodine therapy in the treatment of differentiated thyroid cancer.放射性碘定量治疗分化型甲状腺癌

Q J Nucl Med. 1999 Dec;43(4):313-23.

[Recombinant human thyrotropin in the follow-up of patients with differentiated thyroid carcinoma].[重组人促甲状腺素在分化型甲状腺癌患者随访中的应用]

Rev Esp Med Nucl. 2003 Sep-Oct;22(5):295-305. doi: 10.1016/s0212-6982(03)72206-x.

Blood and bone marrow dosimetry in radioiodine therapy of differentiated thyroid cancer after stimulation with rhTSH.重组人促甲状腺素刺激后分化型甲状腺癌放射性碘治疗中的血液和骨髓剂量测定

J Nucl Med. 2005 May;46(5):900-1; author reply 901.

Blood and bone marrow dosimetry in radioiodine therapy of thyroid cancer.甲状腺癌放射性碘治疗中的血液和骨髓剂量测定

J Nucl Med. 2005 May;46(5):899-900; author reply 901.

Iodine biokinetics and radioiodine exposure after recombinant human thyrotropin-assisted remnant ablation in comparison with thyroid hormone withdrawal.重组人促甲状腺激素辅助残余消融后碘生物动力学和放射性碘暴露与甲状腺激素停药的比较。

J Clin Endocrinol Metab. 2010 Jul;95(7):3283-90. doi: 10.1210/jc.2009-2528. Epub 2010 Apr 14.

Patient-specific dosimetry for 131I thyroid cancer therapy using 124I PET and 3-dimensional-internal dosimetry (3D-ID) software.使用¹²⁴I正电子发射断层显像（PET）和三维体内剂量测定法（3D-ID）软件进行¹³¹I甲状腺癌治疗的个体化剂量测定。

J Nucl Med. 2004 Aug;45(8):1366-72.

引用本文的文献

Radioiodine Exhalation Following Oral I-131 Administration in a Mouse Model.小鼠模型口服 I-131 后放射性碘呼出情况

Biomedicines. 2025 Apr 8;13(4):897. doi: 10.3390/biomedicines13040897.

Whole-body effective half-life of radioiodine in children and young adults with papillary thyroid cancer.儿童和年轻乳头状甲状腺癌患者体内放射性碘的全身有效半衰期。

Endocrine. 2025 May;88(2):537-544. doi: 10.1007/s12020-025-04183-1. Epub 2025 Feb 2.

Investigation of the Suitability of a Commercial Radiation Sensor for Pretherapy Dosimetry of Radioiodine Treatment Patients.商业化辐射传感器用于碘-131 治疗患者治疗前剂量学的适用性研究。

Sensors (Basel). 2022 Dec 1;22(23):9392. doi: 10.3390/s22239392.

Gender differences in estimating I-131 thyroid uptake from Tc-99m thyroid uptake for benign thyroid disease.基于锝-99m甲状腺摄取量估算良性甲状腺疾病患者碘-131甲状腺摄取量的性别差异

Br J Radiol. 2021 Feb 1;94(1118):20200700. doi: 10.1259/bjr.20200700. Epub 2020 Dec 11.

Nine Genes Mediate the Therapeutic Effects of Iodine-131 Radiotherapy in Thyroid Carcinoma Patients.九种基因介导碘-131 放疗治疗甲状腺癌患者的疗效。

Dis Markers. 2020 Jun 16;2020:9369341. doi: 10.1155/2020/9369341. eCollection 2020.

Red bone marrow dose estimation using several internal dosimetry models for prospective dosimetry-oriented radioiodine therapy.使用多种内部剂量测定模型进行前瞻性剂量测定导向的放射性碘治疗的红骨髓剂量估计。

Radiat Environ Biophys. 2018 Nov;57(4):395-404. doi: 10.1007/s00411-018-0757-2. Epub 2018 Oct 8.

Comparing pre-therapeutic I and I uptake tests with intra-therapeutic I uptake in benign thyroid disorders.比较良性甲状腺疾病治疗前碘摄取试验与治疗期间碘摄取情况。

Endocrine. 2017 Apr;56(1):43-53. doi: 10.1007/s12020-017-1267-8. Epub 2017 Mar 7.

The "reset button" revisited: why high activity I therapy of advanced differentiated thyroid cancer after dosimetry is advantageous for patients.再探“重置按钮”：为何剂量测定后对晚期分化型甲状腺癌进行高活性碘治疗对患者有益。

Eur J Nucl Med Mol Imaging. 2017 Jun;44(6):915-917. doi: 10.1007/s00259-017-3649-9. Epub 2017 Feb 16.

Personalized Medicine Based on Theranostic Radioiodine Molecular Imaging for Differentiated Thyroid Cancer.基于诊疗一体化放射性碘分子成像的分化型甲状腺癌个性化医学

Biomed Res Int. 2016;2016:1680464. doi: 10.1155/2016/1680464. Epub 2016 Apr 28.

The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy.分子放疗临床实践中内照射剂量学应用的证据基础。

Eur J Nucl Med Mol Imaging. 2014 Oct;41(10):1976-88. doi: 10.1007/s00259-014-2824-5. Epub 2014 Jun 11.

本文引用的文献

Dosimetry-guided high-activity (131)I therapy in patients with advanced differentiated thyroid carcinoma: initial experience.剂量引导的高活度（131）碘治疗晚期分化型甲状腺癌：初步经验。

Eur J Nucl Med Mol Imaging. 2010 May;37(5):896-903. doi: 10.1007/s00259-009-1303-x. Epub 2009 Dec 24.

The effectiveness of 124I PET/CT in patients with differentiated thyroid cancer.124I正电子发射断层显像/X线计算机体层成像（PET/CT）在分化型甲状腺癌患者中的有效性

Q J Nucl Med Mol Imaging. 2009 Oct;53(5):536-45.

Radioiodine therapy of benign thyroid disorders: what are the effective thyroidal half-life and uptake of 131I?良性甲状腺疾病的放射性碘治疗：131I的有效甲状腺半衰期及摄取率是多少？

Nucl Med Commun. 2010 Mar;31(3):201-5. doi: 10.1097/MNM.0b013e328333d303.

Thyroid remnant dose: 124I-PET/CT dosimetric comparison of rhTSH versus thyroid hormone withholding before radioiodine remnant ablation in differentiated thyroid cancer.甲状腺残留剂量：分化型甲状腺癌放射性碘残留消融术前，重组人促甲状腺素与甲状腺激素抑制状态下124I-PET/CT剂量学比较

Exp Clin Endocrinol Diabetes. 2010 Jul;118(7):393-9. doi: 10.1055/s-0029-1225350. Epub 2009 Oct 23.

124I PET-based 3D-RD dosimetry for a pediatric thyroid cancer patient: real-time treatment planning and methodologic comparison.基于124I正电子发射断层扫描的三维放射性剂量测定法用于一名儿童甲状腺癌患者：实时治疗计划与方法学比较

J Nucl Med. 2009 Nov;50(11):1844-7. doi: 10.2967/jnumed.109.066738. Epub 2009 Oct 16.

A dose-effect correlation for radioiodine ablation in differentiated thyroid cancer.放射性碘消融治疗分化型甲状腺癌的剂量效应关系。

Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):270-5. doi: 10.1007/s00259-009-1261-3. Epub 2009 Sep 4.

Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-analysis.放射性碘估算活性与计算活性治疗甲状腺功能亢进症后的临床结局：系统评价与荟萃分析

Eur J Endocrinol. 2009 Nov;161(5):771-7. doi: 10.1530/EJE-09-0286. Epub 2009 Aug 11.

Blood dosimetry from a single measurement of the whole body radioiodine retention in patients with differentiated thyroid carcinoma.对分化型甲状腺癌患者全身放射性碘滞留的单次测量进行血药剂量测定。

Endocr Relat Cancer. 2009 Dec;16(4):1283-9. doi: 10.1677/ERC-09-0076. Epub 2009 Jul 23.

Accuracy of two simple methods for estimation of thyroidal 131I kinetics for dosimetry-based treatment of Graves' disease.两种用于估算甲状腺 131I 动力学以进行基于剂量测定的格雷夫斯病治疗的简单方法的准确性。

Med Phys. 2009 Apr;36(4):1212-8. doi: 10.1118/1.3093237.

Radioiodine therapy for thyroid volume reduction of large goitres.放射性碘治疗用于缩小大甲状腺肿的甲状腺体积

Nucl Med Commun. 2009 Jun;30(6):466-71. doi: 10.1097/MNM.0b013e32832b5ccc.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验